AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2

Hui Ping Lin; Ching Yu Lin; Chieh Huo; Yee Jee Jan; Jen Chih Tseng; Shih Sheng Jiang; Ying Yu Kuo; Shyh Chang Chen; Chih Ting Wang; Tzu Min Chan; Jun Yang Liou; John Wang; Wun Shaing Wayne Chang; Chung Ho Chang; Hsing Jien Kung; Chih Pin Chuu

doi:10.18632/oncotarget.4553

AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2

Hui Ping Lin, Ching Yu Lin, Chieh Huo, Yee Jee Jan, Jen Chih Tseng, Shih Sheng Jiang, Ying Yu Kuo, Shyh Chang Chen, Chih Ting Wang, Tzu Min Chan, Jun Yang Liou, John Wang, Wun Shaing Wayne Chang, Chung Ho Chang, Hsing Jien Kung, Chih Pin Chuu

Research output: Contribution to journal › Article › peer-review

40 Citations (Scopus)

Abstract

The qRT-PCR analysis of 139 clinical samples and analysis of 150 on-line databaseclinical samples indicated that AKT3 mRNA expression level was elevated in primaryprostate tumors. Immunohistochemical staining of 65 clinical samples revealed thatAKT3 protein expression was higher in prostate tumors of stage I, II, III as comparedto nearby normal tissues. Plasmid overexpression of AKT3 promoted cell proliferationof LNCaP, PC-3, DU-145, and CA-HPV-10 human prostate cancer (PCa) cells, whileknockdown of AKT3 by siRNA reduced cell proliferation. Overexpression of AKT3increased the protein expression of total AKT, phospho-AKT S473, phospho-AKT T308,B-Raf, c-Myc, Skp2, cyclin E, GSK3β, phospho-GSK3β S9, phospho-mTOR S2448, andphospho-p70S6K T421/S424, but decreased TSC1 (tuberous sclerosis 1) and TSC2(tuberous Sclerosis Complex 2) proteins in PC-3 PCa cells. Overexpression of AKT3also increased protein abundance of phospho-AKT S473, phospho-AKT T308, andB-Raf but decreased expression of TSC1 and TSC2 proteins in LNCaP, DU-145, andCA-HPV-10 PCa cells. Oncomine datasets analysis suggested that AKT3 mRNA levelwas positively correlated to BRAF. Knockdown of AKT3 in DU-145 cells with siRNAincreased the sensitivity of DU-145 cells to B-Raf inhibitor treatment. Knockdown ofTSC1 or TSC2 promoted the proliferation of PCa cells. Our observations implied thatAKT3 may be a potential therapeutic target for PCa treatment.

Original language	English
Pages (from-to)	27097-27112
Number of pages	16
Journal	Oncotarget
Volume	6
Issue number	29
DOIs	https://doi.org/10.18632/oncotarget.4553
Publication status	Published - Jan 1 2015
Externally published	Yes

Keywords

Akt3
B-Raf
Proliferation
Prostate cancer
TSC1/2

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.4553

Cite this

Lin, H. P., Lin, C. Y., Huo, C., Jan, Y. J., Tseng, J. C., Jiang, S. S., Kuo, Y. Y., Chen, S. C., Wang, C. T., Chan, T. M., Liou, J. Y., Wang, J., Wayne Chang, W. S., Chang, C. H., Kung, H. J., & Chuu, C. P. (2015). AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2. Oncotarget, 6(29), 27097-27112. https://doi.org/10.18632/oncotarget.4553

@article{09a7f533124b40baa5573acfed0d3248,

title = "AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2",

abstract = "The qRT-PCR analysis of 139 clinical samples and analysis of 150 on-line databaseclinical samples indicated that AKT3 mRNA expression level was elevated in primaryprostate tumors. Immunohistochemical staining of 65 clinical samples revealed thatAKT3 protein expression was higher in prostate tumors of stage I, II, III as comparedto nearby normal tissues. Plasmid overexpression of AKT3 promoted cell proliferationof LNCaP, PC-3, DU-145, and CA-HPV-10 human prostate cancer (PCa) cells, whileknockdown of AKT3 by siRNA reduced cell proliferation. Overexpression of AKT3increased the protein expression of total AKT, phospho-AKT S473, phospho-AKT T308,B-Raf, c-Myc, Skp2, cyclin E, GSK3β, phospho-GSK3β S9, phospho-mTOR S2448, andphospho-p70S6K T421/S424, but decreased TSC1 (tuberous sclerosis 1) and TSC2(tuberous Sclerosis Complex 2) proteins in PC-3 PCa cells. Overexpression of AKT3also increased protein abundance of phospho-AKT S473, phospho-AKT T308, andB-Raf but decreased expression of TSC1 and TSC2 proteins in LNCaP, DU-145, andCA-HPV-10 PCa cells. Oncomine datasets analysis suggested that AKT3 mRNA levelwas positively correlated to BRAF. Knockdown of AKT3 in DU-145 cells with siRNAincreased the sensitivity of DU-145 cells to B-Raf inhibitor treatment. Knockdown ofTSC1 or TSC2 promoted the proliferation of PCa cells. Our observations implied thatAKT3 may be a potential therapeutic target for PCa treatment.",

keywords = "Akt3, B-Raf, Proliferation, Prostate cancer, TSC1/2",

author = "Lin, {Hui Ping} and Lin, {Ching Yu} and Chieh Huo and Jan, {Yee Jee} and Tseng, {Jen Chih} and Jiang, {Shih Sheng} and Kuo, {Ying Yu} and Chen, {Shyh Chang} and Wang, {Chih Ting} and Chan, {Tzu Min} and Liou, {Jun Yang} and John Wang and {Wayne Chang}, {Wun Shaing} and Chang, {Chung Ho} and Kung, {Hsing Jien} and Chuu, {Chih Pin}",

year = "2015",

month = jan,

day = "1",

doi = "10.18632/oncotarget.4553",

language = "English",

volume = "6",

pages = "27097--27112",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals LLC",

number = "29",

}

TY - JOUR

T1 - AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2

AU - Lin, Hui Ping

AU - Lin, Ching Yu

AU - Huo, Chieh

AU - Jan, Yee Jee

AU - Tseng, Jen Chih

AU - Jiang, Shih Sheng

AU - Kuo, Ying Yu

AU - Chen, Shyh Chang

AU - Wang, Chih Ting

AU - Chan, Tzu Min

AU - Liou, Jun Yang

AU - Wang, John

AU - Wayne Chang, Wun Shaing

AU - Chang, Chung Ho

AU - Kung, Hsing Jien

AU - Chuu, Chih Pin

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The qRT-PCR analysis of 139 clinical samples and analysis of 150 on-line databaseclinical samples indicated that AKT3 mRNA expression level was elevated in primaryprostate tumors. Immunohistochemical staining of 65 clinical samples revealed thatAKT3 protein expression was higher in prostate tumors of stage I, II, III as comparedto nearby normal tissues. Plasmid overexpression of AKT3 promoted cell proliferationof LNCaP, PC-3, DU-145, and CA-HPV-10 human prostate cancer (PCa) cells, whileknockdown of AKT3 by siRNA reduced cell proliferation. Overexpression of AKT3increased the protein expression of total AKT, phospho-AKT S473, phospho-AKT T308,B-Raf, c-Myc, Skp2, cyclin E, GSK3β, phospho-GSK3β S9, phospho-mTOR S2448, andphospho-p70S6K T421/S424, but decreased TSC1 (tuberous sclerosis 1) and TSC2(tuberous Sclerosis Complex 2) proteins in PC-3 PCa cells. Overexpression of AKT3also increased protein abundance of phospho-AKT S473, phospho-AKT T308, andB-Raf but decreased expression of TSC1 and TSC2 proteins in LNCaP, DU-145, andCA-HPV-10 PCa cells. Oncomine datasets analysis suggested that AKT3 mRNA levelwas positively correlated to BRAF. Knockdown of AKT3 in DU-145 cells with siRNAincreased the sensitivity of DU-145 cells to B-Raf inhibitor treatment. Knockdown ofTSC1 or TSC2 promoted the proliferation of PCa cells. Our observations implied thatAKT3 may be a potential therapeutic target for PCa treatment.

AB - The qRT-PCR analysis of 139 clinical samples and analysis of 150 on-line databaseclinical samples indicated that AKT3 mRNA expression level was elevated in primaryprostate tumors. Immunohistochemical staining of 65 clinical samples revealed thatAKT3 protein expression was higher in prostate tumors of stage I, II, III as comparedto nearby normal tissues. Plasmid overexpression of AKT3 promoted cell proliferationof LNCaP, PC-3, DU-145, and CA-HPV-10 human prostate cancer (PCa) cells, whileknockdown of AKT3 by siRNA reduced cell proliferation. Overexpression of AKT3increased the protein expression of total AKT, phospho-AKT S473, phospho-AKT T308,B-Raf, c-Myc, Skp2, cyclin E, GSK3β, phospho-GSK3β S9, phospho-mTOR S2448, andphospho-p70S6K T421/S424, but decreased TSC1 (tuberous sclerosis 1) and TSC2(tuberous Sclerosis Complex 2) proteins in PC-3 PCa cells. Overexpression of AKT3also increased protein abundance of phospho-AKT S473, phospho-AKT T308, andB-Raf but decreased expression of TSC1 and TSC2 proteins in LNCaP, DU-145, andCA-HPV-10 PCa cells. Oncomine datasets analysis suggested that AKT3 mRNA levelwas positively correlated to BRAF. Knockdown of AKT3 in DU-145 cells with siRNAincreased the sensitivity of DU-145 cells to B-Raf inhibitor treatment. Knockdown ofTSC1 or TSC2 promoted the proliferation of PCa cells. Our observations implied thatAKT3 may be a potential therapeutic target for PCa treatment.

KW - Akt3

KW - B-Raf

KW - Proliferation

KW - Prostate cancer

KW - TSC1/2

UR - http://www.scopus.com/inward/record.url?scp=84944472711&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944472711&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.4553

DO - 10.18632/oncotarget.4553

M3 - Article

C2 - 26318033

AN - SCOPUS:84944472711

SN - 1949-2553

VL - 6

SP - 27097

EP - 27112

JO - Oncotarget

JF - Oncotarget

IS - 29

ER -

AKT3 promotes prostate cancer proliferation cells through regulation of Akt, B-Raf & TSC1/TSC2

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this